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Objective: To investigate the antibacterial activity of SHH extracted with either water or
ethanol against methicillin-resistant Staphylococcus aureus (MRSA) and combinatory
antimicrobial effect with ciproﬂoxacin (CIP) by time kill assay and checkerboard dilution
test.
Methods: The antibacterial activity determined by broth dilution method indicated that
the antibacterial activity of Sami-Hyanglyun-Hwan (SHH) water extract (SHHW) and
SHH ethanol extract (SHHE) ranged from 250 to 2000 mg/mL and 125 to 1000 mg/mL
against MRSA, respectively.
Results: In the checkerboard method, the combinations of SHHE with CIP had a partial
synergistic or synergistic effect against MRSA. The time-kill curves showed that a
combined SHHE and CIP treatment reduced the bacterial counts dramatically after 24 h.
Conclusions: The present study demonstrates the therapeutic ability of SHHE against
MRSA infections.1. Introduction
Staphylococcus aureus (S. aureus) is a commensal of the
human skin, gastrointestinal tract and nares. It causes skin and soft
tissue infections, invasive disease, sepsis, and endocarditis [1].
The treatment of S. aureus infections has been evolved by the
antibiotic-resistant strains, called methicillin-resistant S. aureus
(MRSA), that have increased resistance feature against infectious
diseases therapeutics [2]. MRSA is a human pathogen and a cause
of hospital-acquired and community-acquired infections. It is amajor global health concern resulting in nearly 20000 deaths in
the United States alone [3]. MRSA isolates are resistant to all
possible penicillin and other b-lactam [4]. Antibiotic resistance
in MRSA has resulted in limited treatment options. Thus, there
is a critical need for the discovery of new antibiotics in
development against MRSA and treatment strategies to
circumvent this growing public health concern.
Studies have demonstrated that combination drug therapy is a
more effective alternative to slow down or stop development of
drug resistance against bacteria [5] and is recommended
treatment for bacterial infections such as MRSA [6].
Sami-Hyanglyun-Hwan (SHH), is a traditional Korean
medicine (TKM) prescription that has been used for several
hundred years by the Korean community. This classical botan-
ical formulation consists of four Korean herbs that include the
Coptidis rhizoma (C. rhizoma), Rhei rhizoma (R. rhizoma),
Aucklandiae radix (A. radix) and Arecae semen (A. semen).en access article under the CC BY-NC-ND
Table 1
Determination of the mecA gene of the S. aureus strains used in the
experiment.
Strains Serotypes Class mecA
gene
b-Lactamase
activity
Antibiotic
resistance
pattern
WK-1 ATCC 25923 MSSA − − −
WK-2 ATCC 33591 MRSA + + AM, OX
WK-3 aDPS-1 MRSA + + AM, OX
WK-4 DPS-5 MRSA + − AM, OX
WK-5 CCARM 3090 MRSA + + AM, OX, CIP
Wk-6 CCARM 3091 MRSA + + AM, OX, CIP
WK-7 CCARM 3095 MRSA + + AM, OX, CIP
WK-8 CCARM 3102 MRSA + + AM, OX, CIP
a DPS indicates staphylococcal strains from the Department of Plastic
Surgery, Wonkwang University Hospital. AM, ampicillin; OX,
oxacillin; CIP, ciproﬂoxacin.
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Recently, research in herbs prescribed in TKM has attracted
great attention as many of them have been shown to exhibit
numerous biological activities including anti-virus [7], anti-
inﬂammatory effects [8,9] and anti-cancer [10,11]. Ciproﬂoxacin
(CIP) a well-known broad range antibiotic working against
both gram positive and gram negative bacteria and widely used
for common pathogen causing infections [8,9]. In an effort to
discover novel antibacterial agents or antiviral formulations
from TKM, SHH, one of the most frequently used Korean
prescriptions, was investigated for its in vitro antibacterial
activity. We herein report also, the promising anti-MRSA syn-
ergy of CIP combined with SHH extracted with ethanol.
2. Materials and methods
2.1. Plant materials
C. rhizoma, R. rhizoma, A. radix and A. semen were pur-
chased from the Oriental drug store Daehak Hanyakkuk (Iksan,
Korea), and authenticated by Dr. D.Y. Kwon. All voucher
specimens were deposited in the Laboratory of Herbalogy,
College of Pharmacy, Wonkwang University, Iksan, Korea.
2.2. Preparation of the SHH water or ethanol extracts
A total of 500 mL of de-ionized distilled water (dd water) or
70% EtOH were added to 26 g of SHH prescription, which 15 g
of C. rhizoma, 6 g of R. rhizoma, 3 g of A. radix and 2 g of
A. semen was heated until the preparation boiled. After 2 h the
decoction was then percolated to obtain ﬁltrate, and drugs were
re-boiled with fresh 500 mL of dd water or 70% EtOH. After
two more rounds of percolation and ﬁltration, collected ﬁltrates
were then poured together, concentrated under reduced pressure,
lyophilized stored at −20 C until use. The yield of the SHH
water extract was 17.4% (4.53 g) and EtOH extract was 14.2%.
2.3. Bacterial strains and culture medium
Among the 8 strains of S. aureus used in this study, 2 clinical
MRSA isolates were obtained from 2 different patients at
Wonkwang University Hospital and 2 strains were commercially
purchased S. aureus ATCC 33591 (methicillin-resistant strain)
and S. aureus ATCC 25923 [methicillin-susceptible strain
(MSSA)] (American Type Culture Collection, Manassas, VA).
The remaining 4 strains were obtained from Culture Collection
of Antimicrobial Resistant Microbes. All bacteria were stored as
30% glycerol stocks and frozen at −70 C until use. The bac-
terial strains were suspended in Mueller-Hinton broth (MHB)
and incubated at 37 C for 24 h.
2.4. Antimicrobial reagents
MHB and Mueller-Hinton agar (MHA) (Difco Laboratories,
Baltimore, MD, USA). Ampicillin, oxacillin, CIP, erythromycin,
and solventswere purchased fromSigmaAldrich (St. Louis, USA).
2.5. Antimicrobial resistance testing
Detection of the mecA gene in MRSA strains was performed
by polymerase chain reaction (PCR) ampliﬁcation (Table 1).Prior to DNA extraction, bacteria stock cultures were subcultured
twice on to MHA plates. For rapid extraction, one to ﬁve bacterial
colonies were suspended in 300 mL of cell lysis buffer and heated
at 100 C for 20 min. After centrifugation at 12000 rpm for
10 min, 2 mL of the supernatant was used for the DNA extraction.
PCR reactions were performed using a MRSA Primer Mix Kit
(Genotek, Daejeon, Republic of Korea). The PCR ampliﬁcation
was consisted of 30 cycles (94 C, 60 s; 55 C, 60 s; 72 C, 60 s).
The ﬁnal PCR products were separated on a 2% agarose gel.
2.6. Disc diffusion
The paper disc diffusion method was used to determine anti-
bacterial activity [10]. Sterile paper discs (6 mm; Toyo Roshi
Kaihsa, Japan) were loaded with 20 mL of SHHW or SHHE
(varying concentrations: 50, 100, and 200 mg) dissolved in
10% dimethyl sulfoxide (DMSO, Sigma, USA), and were left
to dry for 12 h at 37 C under sterile conditions. The bacterial
suspensions were diluted to match the 0.5 McFarland standard
scale (approximately 1.5 × 108 CFU/mL), and were further
diluted to obtain the ﬁnal inoculum. The MHA was poured
into petri dishes and inoculated with 100 mL of the suspension
containing 1 × 105 CFU of bacteria. The inhibition zone
diameter around each of the discs was measured and recorded
at the end of the incubation period. Ampicillin was included
as positive control and 10% DMSO served as negative controls.
2.7. Determination of the minimum inhibitory
concentrations (MICs)
The MIC determinations were performed using the broth
microdilution method described by the Clinical and Laboratory
Standard Institute guidelines [11]. Serial 2-fold dilutions of SHHW
or SHHE inMHBwere prepared in sterile 96-well microplates and
microtubes. The MRSA inocula were adjusted to the 0.5 McFar-
land standard [approximately colony-forming units (CFU)/mL] in
MHB. The ﬁnal inocula were adjusted toCFU/spot. The MIC was
deﬁned as the lowest concentration of SHHE that permits micro-
organism growth after prior incubation at 37 C for 24 h.
2.8. Checkerboard dilution test
The checkerboard method was used to identify the in-
teractions between SHHE and antibiotics [12]. The antimicrobial
Table 2
Antimicrobial activity (as the inhibition zone diameter) of SSH against 8
methicillin-resistant S. aureus (mm).
Strains Serotypes SSH EtOH ext. SSH H2O ext.
50 mg 100 mg 200 mg 50 mg 100 mg 200 mg
WK-1 ATCC 25923 10 12 15 12 11 15
WK-2 ATCC 33591 ND ND 7 ND ND ND
WK-3 DPS-1 ND 7 12 ND ND ND
WK-4 DPS-5 ND ND 12 ND ND ND
WK-5 CCARM 3090 ND 8 10 ND ND ND
Wk-6 CCARM 3091 ND 7 9 ND ND ND
WK-7 CCARM 3095 ND 7 9 ND ND ND
WK-8 CCARM 3102 ND 9 12 ND ND 7
ND: No detected activity at this concentration.
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Serial dilutions of SHHE with these antibiotics were mixed in
cation-supplemented MHB. The inocula were prepared from
colonies that had been grown on MHA overnight. The ﬁnal
bacterial concentration after inoculation was CFU/spot. The
MIC, determined after incubation at 37 C for 24 h, was
deﬁned as the lowest concentration of drug, alone or in
combination with other agents that visibly inhibited the growth
of bacteria. Each experiment was performed 3 times. The
in vitro interaction between the drugs was quantiﬁed by
determining the fractional inhibitory concentration (FIC). The
FIC index (FICI) was calculated with the following formula:
FICI = FICA + FICB = [A]/MICA + [B]/MICB, where [A] and
[B] are the concentrations of drug A and B, respectively, and
MICA/FICA and MICB/FICB are the MIC/FIC of drug A and
B, respectively. The FICI was interpreted as follows: 0.5,
synergy; >0.5–0.75, partial synergy; >0.75–1, additive effect;
>1–4, no effect; and >4, antagonism. Finally, the different
values of synergy between the 2 agents were calculated [12].
2.9. Time-kill assay
Time-kill curves were used to determine the synergy effects
of the 2 antimicrobial agents on bacterial growth in 96-well
plates at 5 different time points (0, 4, 8, 16, and 24 h) [13].
Bacterial cultures diluted with fresh MHB to approximately
CFU/mL, and the diluted cultures were incubated at 37 C for
24 h. Aliquots (0.1 mL) of the culture were taken at 0, 4, 8,
16, and 24 h of incubation, and serial 10-fold dilutions were
prepared in saline as needed. The numbers of viable cells were
determined on a drug-free MHA plate after incubation for
24 h. Colony counts were performed on plates, and 30–300
colonies were enumerated. The lower limit of sensitivity of the
colony counts was 100 CFU/mL. The antimicrobial agents used
were considered bactericidal at the lowest concentration that
reduced the original inoculum by 3 log10 CFU/mL (99.9%) for
each of the indicated times. However, they were designated
bacteriostatic if the inoculum was reduced by only 0–3
log10 CFU/mL. To conﬁrm the results, the time-kill assays for
each experiment were performed at least thrice; the data are
represented as mean data ± standard deviation [13].Table 3
MIC of the 8 methicillin-resistant S. aureus (mg/mL).
Strains Serotypes MIC
SSH EtOH ext. SSH H2O ext.
WK-1 ATCC 25923 125 1000
WK-2 ATCC 33591 1000 1000
WK-3 DPS-1 500 1000
WK-4 DPS-5 500 1000
WK-5 CCARM 3090 500 1000
Wk-6 CCARM 3091 500 2000
WK-7 CCARM 3095 1000 2000
WK-8 CCARM 3102 1000 20003. Results
3.1. Anti-bacterial activity of SHHW and SHHE against
MRSA
The antimicrobial efﬁcacy of SHHW and SHHE against the
MRSA strains was evaluated by the disc diffusion method via
determination of the surrounding inhibition zones, as well as by
evaluating the MIC using the broth micro dilution method. Both
the extracts of SHH extracted either by water or ethanol showed
antimicrobial activity against MSSA strains. However, the
SHHW extract appeared to work only at the highest concen-
tration tested against one strain of MRSA (200 mg for WK-8,
Table 2) showing disc diffusion zone of 7 mm. The SHHE
showed antimicrobial activity against all the MRSA strains at
200 mg concentration as determined by disc diffusion method.
There was a dose dependent activity of SHHE against the strains
of MRSA/MSSA as shown in Table 2. Thus, SHHE was able to
restrict bacterial growth successfully in different MRSA strainsresistant to ampicillin, oxacillin or ciproﬂoxacin. Similarly, the
MICs needed for antimicrobial activity against all the MRSA
strains varied considerably between the two extracts of SHH.
For SHHW, the MICs determined using the broth dilution
method showed that at least 2–4 fold higher concentration was
needed to reach MIC as compared to SHHE. The MIC for
SHHW ranged from 1000 to 2000 mg/mL, as compared to a
signiﬁcantly lower concentration needed for SHHE ranging from
125 to 1000 mg/mL. Thus, we demonstrated that SHHE extract
had more strong antibacterial activity against MRSA as
compared to SHHW (Table 3).
3.2. Synergistic testing
The synergistic effects of SHHE with CIP were tested on four
MRSA strains by using a checkerboard dilution assay. The effect
of SHHE alone or SHHE combined with CIP was tested towards
antimicrobial activity. The MIC results showed that combina-
torial effects of SHHE with CIP had 2–32 fold reduction in
concentration as those needed by SHHE alone. The antibacterial
effects of SHHE and CIP alone or SHHE combined with CIP are
shown in Table 4. The antibacterial activity of SHHE markedly
reduced the MICs of CIP against S. aureus strains. Thus, a
signiﬁcantly lower dose of SHHE would be required to achieve
the same antimicrobial activity with CIP as compared to the
extract alone. These results demonstrated that the combination
of SHHE with CIP could be used to suppress MRSA growth.
3.3. Time-kill curve assay
The synergistic effects of SHHE with CIP on MRSA were
conﬁrmed with a time-kill curve assay on two strains WK-5 and
Table 4
Result of the combined effect of SHHE and CIP against methicillin-resistant S. aureus.
Strains Serotypes MIC SHHE (mg/mL) MIC CIP (mg/mL) FICI Outcome
Alone With CIP Alone With SHHE
WK-2 ATCC 33591 1000 125 0.24 0.06 0.37 Synergy
WK-5 CCARM 3090 500 250 >1000 250 0.62 Partial synergy
WK-7 CCARM 3095 1000 500 >1000 125 0.62 Partial synergy
WK-8 CCARM 3102 1000 500 >1000 31.25 0.51 Partial synergy
FICI, fractional inhibitory concentration index.
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either SHHE alone (1/2 MIC) or CIP alone (1/2MIC) inhibition
MRSA growth by just 3–5 log. However, when used together,
the combination of SHHE and CIP caused rapid inhibition in a
time-dependent process during an observation period of 24 h
showing an eight log difference in bacterial growth. Thus, a
synergist effect was observed when both SHHE and CIP were
used together. Similar results were seen with strain WK-8. As
shown in Figure 2, the combination of SHHE and CIP almost
completely inhibited the growth of MRSA after 24 h. the dif-
ference between SHHE or CIP alone was 4–6 log decrease in
bacterial growth, however with both combined, there was 11
fold (~90%) reduction showing the promising synergist aspect
of both used together. Thus, SHHE extracts isolated in our
laboratory along with commercially available CIP should be
used together to achieve almost complete control of MRSAFigure 1. Time-kill curve for CCARM 3090 (WK-5) when using SHHE
and CIP. SHHE 1/2 MIC (250 mg/mL); CIP 1/2 MIC (500 mg/mL); SHHE
1/2 MIC (250 mg/mL) + CIP 1/2 MIC (500 mg/mL).
Figure 2. Time-kill curve for CCARM 3102 (WK-8) when using SHHE
and CIP. SHHE 1/2 MIC (500 mg/mL); CIP 1/2 MIC (500 mg/mL); SHHE
1/2 MIC (500 mg/mL) + CIP 1/2 MIC (500 mg/mL).strains that are almost impossible to control due to their inherent
nature.
4. Discussion
In this study, we have demonstrated that SHHE was found to
inhibit against bothMSSAandMRSA.Although it could inhibit the
growth of both bacteria, the ethanol extracts of SHH demonstrated
higher antimicrobial activity against MRSA than the water extract
of SHH. Consequently, SHHE may be used potent antibacterial
agents to be used in combating drug-resistant S. aureus strains.
MRSA began as a acquire resistance to most of antibiotics
have signiﬁcantly increased the global mortality caused by
multidrug-resistant bacterial infection [14,15]. Ciproﬂoxacin is the
antibiotic of selected for treating skin and soft tissue infections
in areas where bacteria such as MRSA and Salmonella are
prevalent [16,17]. Recently, many reports have shown that
infections due to strains of MRSA with a high-level resistance
to ﬂuoroquinolones are particularly worrying. The emergence of
complete resistance to CIP in MRSA would severely limit the
choice of antimicrobial therapies for treating infection [17–20].
To overcome the emerging problem of multi-drug resistant
bacterial strains, various studies investigating combinations of
plant extracts with antibiotics against MRSA have been reported
[21–23]. The use of two antibiotics in combination is slow in the
process drug resistance and to restore the activity of drugs that
are no longer treatment. Combination therapy is the most
commonly recommended empirical treatment for bacterial
infections and for preventing the emergence of resistant
mutants for bacteria [6]. In this study, we conﬁrm that SHHE
has antimicrobial activity and combining sub-MIC concentra-
tions of SHHE with CIP signiﬁcantly improved the activity of
the antibiotic by a checkerboard dilution assay. In addition, the
combination of 1/2MIC SHHE + 1/2MIC CIP completely
inhibited the growth of MRSA (WK-8) after 24 h by time-kill
curve assay. Thus, SHHE was shown to have an effect on the
CIP activity, plus the in vitro activity of SHHE against MRSA
and its synergistic interactions with CIP were demonstrated for
the ﬁrst time. Therefore, SHHE has the potential to restore the
effectiveness of CIP against resistant MRSA, and could be
useful in developing valuable clinical treatments.
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